Fluvoxamine, a drug that treats obsessive-compulsive disorder, could reduce the risk of respiratory deterioration and subsequent hospitalization in patients with early COVID-19, according to study results published Nov. 12 in the Journal of the American Medical Association.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,